Research
Hormonal
Tirzepatide demonstrates superior body weight reduction compared to semaglutide 2.4 mg and liraglutide 3.0 mg in non-diabetic subjects with obesity.
Among incretin therapies, tirzepatide offers the greatest weight loss potential for non-diabetic individuals with obesity, outperforming semaglutide and liraglutide.
StrongSupportsHIGH confidence
A recent network meta-analysis of RCT comparing incretin-based drugs for the management of obesity in non-diabetic subjects supported the superiority of tirzepatide in achieving a greater percentage of BW loss compared to semaglutide 2.4 mg and liraglutide 3.0 mg
Why this rating
Supported by network meta-analysis of RCTs.
Source
Incretin-based therapies for the treatment of obesity-related diseases
Irene Caruso et al. · npj Metabolic Health and Disease · 2024
narrative_reviewCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →